SPYH:XETRA:XETRA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 239.15

Change

-0.35 (-0.15)%

Market Cap

USD 0.66B

Volume

5.17K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-16 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.17 (+0.33%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.05 (+0.28%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.13 (+0.47%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.07 (+0.25%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.12 (-0.47%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.07%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

+0.02 (+0.01%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.18 (+0.34%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.60 (+0.59%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+3.00 (+0.52%)

USD 80.38B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.86% 93% A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.86% 92% A 89% A-
Trailing 12 Months  
Capital Gain 16.74% 70% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.74% 69% C- 69% C-
Trailing 5 Years  
Capital Gain 65.92% 82% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.92% 82% B 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 8.54% 66% D+ 64% D
Dividend Return 8.54% 65% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.31% 66% D+ 73% C
Risk Adjusted Return 102.79% 97% N/A 97% N/A
Market Capitalization 0.66B 70% C- 62% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike